Research programme: breast cancer antibodies - Antibody Therapeutics
Alternative Names: Breast cancer antibody - Antibody TherapeuticsLatest Information Update: 30 Aug 2021
At a glance
- Originator Antibody Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Breast cancer